🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📰 Lancement officiel du projet européen Path4Young pour optimiser la prise en charge du #cancer du sein chez les jeunes femmes. Lire l'article du @GroupeUnicancer ⤵ unicancer.fr/fr/actualite/l…

Friday's Poster Spotlight Sessions at #SABCS24 covered a wide range of topics, including the impact of immunobiology on therapeutic efficacy, using molecular imaging and AI to guide treatment, and addressing racial disparities in breast cancer outcomes. AACR @UTHealthSAMDA

Metastatic breast cancer remains a major challenge, but CAR-T cell therapy offers hope. Read our new article reviewing preclinical & clinical data, and strategies to enhance CAR-T effectiveness in BC treatment. #BreastCancer #CARtherapy #Immunotherapy ➡️ sciencedirect.com/science/articl…

Current status and future perspective of CAR-T cell therapy for breast cancer - Giuseppe Buono, MD oncodaily.com/url/221935 Martina Pagliuca Roberta Caputo #Cancer #Bcsm #ImmuneOnc #IO #ImmunoOncology #Immunotherapy #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Manca poco al #wcd2025. Al centro della campagna di comunicazione di quest'anno c'è un nuovo approccio assistenziale in #oncologia, centrato pienamente sulla persona. #AIOM #worldcancerday25 #giornatamondialecontroilcancro #unitedbyunique

Key papers oncologia Pubblicazione n. 69 BREAST A cura di ChiaraMolinelli (GE), Davide Soldato (GE) Per visualizzare la pubblicazione: keypapers.it/keypapers-69

New #JITC article: Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma bit.ly/4g1sAed Daniela Esposito Stefania Belli Fabiana Napolitano Luigi Formisano

📰 Path4Young, projet international pour personnaliser la prise en charge des jeunes femmes atteintes de cancer du sein. Dirigé par la Dr Ines Vaz Luis et coordonné par Unicancer, le projet Path4Young vise à transformer la prise en charge des jeunes patientes atteintes de

SAVE THE DATE: Breast Journal Club 📍7-8 marzo, Napoli. Solo pochi giorni alla sedicesima edizione del Breast Journal Club, l’evento di premiazione delle più rilevanti ricerche cliniche nazionali ed internazionali anche condotte da giovani under40. L’edizione 2025 tra gli altri

INNOVAZIONE E RICERCA IN #ONCOLOGIA: un appuntamento da non perdere. Breast Journal Club 📍7-8 Marzo, Napoli. Manca poco alla sedicesima edizione del #BJClub, evento di riferimento dedicato all’evoluzione della ricerca in oncologia, quest’anno con un focus sull’impatto

Truly grateful to be selected for the #ASCO25 Annual Meeting Merit Award - for the third year in a row 🎉 Huge thanks to my incredible reasearch team for their dedication and support 🙌🏻Gustave Roussy Cancer Survivorship Group Excited to share our work at the congress! 📊 Gustave Roussy Scuola Superiore Meridionale

🙌 hey #AACR25, check out FabiNapolitanoMD’s poster TOMORROW (Monday) afternoon! Fabiana has identified RTK-mediated mechanisms of adaptation to mutant-selective #PI3K inhibition in #breastcancer. #RLY2608 #HER2 UTSW Simmons Cancer Center

We’re LIVE in Barcelona! Welcome to the 6th EORTC Quality of Life in Cancer Clinical Trials Conference 🎉 2 days, 40+ speakers, and a deep dive into #HRQOL & #PROs in oncology💬 Stay tuned for insights on trial design, patient care & regulatory impact! #QoLConf25 #CancerResearch

Excited to be in Barcelona for the 6th EORTC Quality of Life in Cancer Clinical Trials Conference! A rich and inspiring ✨ 2-day programme focused on advancing PROs and HRQOL in oncology. Can’t wait to learn 📚 from global experts and connect with the community! 🌎 #QoLConf25

New paper published in Cancer Treatment Reviews! What to consider after progression on CDK4/6i in HR+/HER2- mBC? Insights from a panel of Italian experts. Grateful for the opportunity to contribute to this work! 👉 Open access: doi.org/10.1016/j.ctrv…

🚨 New insights in #RETpositive #LungCancer: RET+ NSCLC often express MET & TROP2, moderately HER3 & EGFR, and rarely HER2. ➡️ Multiple membrane targets may co-exist 🧬 Dynamic changes post-treatment — fresh biopsy recommended 💡 Supports ADC & bispecific antibody trials

Excited to share our article out in JAMA Oncology The first to report the expression of membrane targets in RET+ NSCLC in a wide international cohort Have a look: jamanetwork.com/journals/jamao… Gustave Roussy Caris Life Services

🔹 Arianna Marinello presented yesterday outcomes to RETinhibitor re-challenge in advanced NSCLC with RET fusions, from the RET-MAP registry at ASCO 2025. #ASCO @asco

🔹 Lodovica Zullo presented yesterday the results of a pathomics-based prediction analysis of thymic epithelial tumor subtypes.  @asco #ASCO25 #ASCO

🔹 Martina pagliuca presents a hierarchical clustering analysis to dissect behavioural symptoms in early stage breast cancer. a work conducted on CANTO #breastcancer #symptomscience. #ASCO25 #ASCO